当前位置:
首页
网刊
哮喘和慢性阻塞性肺疾病用药现状及新药研究进展
哮喘和慢性阻塞性肺疾病用药现状及新药研究进展
喻 勇1,宁保明2,舒 宏1,魏宁漪2,侯曙光1

1 四川普锐特医药科技有限责任公司,成都 610041;2 中国食品药品检定研究院,北京 102629
Current status and new development of drugs for asthma and chronic obstructive pulmonary disease
(1 Sichuan Purity Pharmaceutical Technology Co.,Ltd.,Chengdu 610041,China;2 National Institutes for Food and Drug Control, Beijing 102629,China)

摘要参考文献相关文章

起始页:159

摘要:[摘要] 本文简述了哮喘及慢性阻塞性肺疾病的发病机理及全球治疗策略的最新进展,汇总了国内外用于治疗哮喘和慢性阻塞性肺疾病药物的分类、适用性、优劣和市场,并就国外新药研究进展进行了分析及展望。

关键词:[关键词] 哮喘;慢性阻塞性肺疾病;治疗策略;药物类别;研究进展

通讯作者:

基金项目:

作者简介:

Abstract:
[Abstract] In this article, the recent progress of pathogenesis and global therapeutic strategies of chronicobstructive pulmonary disease was introduced, the categories, advantages, limitations, and market of the current available drug products was summarized, and the trend of new drug development was analyzed and prospected.

Key words:[Key words] asthma; chronic obstructive pulmonary disease; global guideline; drug category; development trend

    [1] 蒋宝安,屈斌,郑辉,等. 支气管哮喘的发病机制及药物治疗研究进展[J]. 中国当代医药,2015,22(13):35-37.
    [2] 陈辉龙,熊维宁,徐永健. 支气管哮喘治疗新药的开发及临床应用

    [J].世界临床药物,2014,35(6):44-47.
    [3] 段丽娜,王贵佐. 慢性阻塞性肺疾病治疗最新研究进展[J]. 中华临床医师杂志(电子版),2014,8(24):118-121.
    [4] 汤森路透生命科学与制药. 哮喘及慢性阻塞性肺病全球品牌药市场格局及趋势分析[EB/OL].[2017-01-05]. http://www.thomsonscientific.com.cn/lscn/ls-blog/20170105.shtml.
    [5] 吸入制剂. 【吸入+透皮+植入】三大新型释药系统的行业现状与发展机遇[EB/OL].[2017-03-10].http://wx.7399.com/jiankang/797174.html.
    [6] 新药述评. 每日新药速递:酒石酸左旋沙丁胺醇吸入气雾剂[EB/OL].[2016-11-24].http://mp.weixin.qq.com/s/y3bUIT52d7ms1zajMgllLA.
    [7] 舒宏,崔一民,侯曙光. 肺部吸入给药制剂及临床应用[J]. 临床药物治疗杂志,2014,12(2):18-24.
    [8] BOSWELLSMITH V,SPINA D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast[J]. Int J Chron Obstruct Pulmon Dis,2007,2(2):121-129.
    [9] BATEMAN ED,BLEECKER ER,WOODCOCK A,et al. Dose effect of once daily fluticasone furoate in persistent asthma:A randomized trial[J]. Respir Med,2012,106(5):642-650.
    [10] 张志智,卢添宝. 吸入糖皮质激素治疗支气管哮喘的研究进展[J].湖州师范学院学报,2005,27(1):112-115.
    [11] 陈爱欢,钟南山.半胱氨酰白三烯受体拮抗剂与气道炎症[J].国外医学呼吸系统分册,2000,20(2):70-72.
    [12] 王瑞倩,卞涛.选择性磷酸二酯酶抑制剂罗氟司特在慢性阻塞性肺疾病抗炎作用的研究进展[J]. 国际呼吸杂志,2012,32(21):441-446.
    [13] CALVERLEY PM,SANCHEZ-TORIL F,MCLVOR A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease[J]. Am J RespirCrit Care Med,2007,176(2):154-161.
    [14] KOBAYASHI M,NASUHARA Y,BETSUYAKU T,et al. Effect of low-dose theophylline on airway inflammation in COPD[J]. Respirology,2004,9(2):249-254.
    [15] GIEMBYEZ MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized:Guarded optimism or wishful thinking?[J]. Br J Pharmacol,2008,155(3):288-290.
    [16] GIEMBYEZ MA. An update and appraisal of the cilomilast Phase III clinical development progrmnme for chronic obstructive pulmonary disease[J].Br J Pharmacol,2006,62(2):138-152. 
    [17] 乔力松. 罗氟司特:慢性阻塞性肺疾病治疗研究进展[J]. 中国实用医药,2011,6(26):233-235.